NICE | PharmaTimes

First treatment for common bladder cancer recommended by NICE

Ella Day — Thu, 10 Apr 2025 11:22:53 +0000

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration

Chiani-Rae Garland — Thu, 31 Oct 2024 13:00:08 +0000

Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020

Emily Kimber — Mon, 21 Oct 2024 11:17:38 +0000

Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK

PharmaTimes — Tue, 20 Aug 2024 11:50:55 +0000

Osteoporosis currently affects 3.8 million people in the UK, particularly impacting older women after menopause

John Pinching — Mon, 25 Sep 2023 13:11:00 +0000

Therapy has been developed to treat adult patients with newly diagnosed multiple myeloma

John Pinching — Wed, 06 Sep 2023 13:24:00 +0000

Therapy is used among adult patients with symptomatic obstructive hypertrophic cardiomyopathy

John Pinching — Mon, 04 Sep 2023 12:03:00 +0000

The therapy has been developed for the treatment of Fabry disease among adult patients

Jen Brogan — Tue, 22 Aug 2023 12:14:00 +0000

Around 670 people in England with epidermolysis bullosa will benefit from the treatment

John Pinching — Thu, 17 Aug 2023 16:33:00 +0000

The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study

Jen Brogan — Fri, 04 Aug 2023 10:26:00 +0000

Therapy is a treatment option for adults with severe and moderately severe haemophilia B